Clinical Trials Logo

Clinical Trial Summary

Fluid management in septic shock patients remain a great challenge. Insufficient fluid filling lead to hypovolemia, organ failure and increased death, whereas fluid overload was associated to an increased morbidity and mortality in several studies. Several invasive and non invasive strategies have been developed during the past years to monitor the hemodynamic state of septic shock patients, but no method has been validated to objectively quantify fluid overload in septic shock patients. The Body Composition Monitor (BCM) allow for measurement of total body water (TBW), extracellular water (ECW) and intracellular water (ICW) volumes using bioimpedancemetry. The BCW is daily used in patients who undergo renal dialysis to assess the effectiveness of fluid removal. The BCM has never been validated in septic shock patients. The aim of the study is to investigate the accuracy of the BCM to measure the variation of the TBW during a fluid challenge of 500 ml of saline during the early phase of septic shock.


Clinical Trial Description

Patients suffering from septic shock admitted in our critical care unit for less than 24 hours will be eligible. TBW, ECW and ICW volumes will be measured using the BCM just before (T0), just at the end (T1) and 1 h after the end (T2) of a fluid challenge of 500 ml of saline. Fluid responsiveness will be assessed using trans thoracic echocardiography (TTE). TTE will be performed at T0, T1 and T2. Blood samples will be obtained at T0, T1 and T2 to dose biomarkers of endothelial dysfunction and of capillary leak. The effectiveness of fluid challenge on microcirculation will be investigated by measuring the tissue perfusion index of the urethral mucosa using the IKORUS UP device. Patients will be followed until Day 28 after admission in the critical care unit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04114162
Study type Observational
Source Centre Hospitalier Universitaire de Besancon
Contact Guillaume BESCH, M.D., Ph.D.
Phone +33381218958
Email gbesch@chu-besancon.fr
Status Recruiting
Phase
Start date January 1, 2020
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03592693 - Vitamin C, Hydrocortisone and Thiamine for Septic Shock Phase 2
Terminated NCT01639664 - COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2 N/A
Withdrawn NCT01601938 - Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients Phase 2
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00000574 - Ibuprofen in Sepsis Study Phase 3
Recruiting NCT04910841 - Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine N/A
Active, not recruiting NCT04079829 - Postoperative Respiratory Abnormalities
Recruiting NCT04569942 - Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis Phase 3
Recruiting NCT04934943 - "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
Completed NCT01310790 - Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock Phase 4
Completed NCT00241228 - Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care) N/A
Completed NCT00046072 - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis Phase 2
Withdrawn NCT03122678 - Thiamine Supplementation in Patients With Septic Shock Phase 1
Recruiting NCT06155812 - Multimodal Vasopressor Strategy in Septic Shock Phase 2/Phase 3
Completed NCT04178148 - Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock N/A
Completed NCT01453270 - Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial N/A
Completed NCT04576819 - Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
Active, not recruiting NCT04055909 - Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock Phase 2
Suspended NCT03193164 - Neuromuscular Electrical Stimulation and Septic Shock N/A
Completed NCT04647552 - Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock